{
    "nctId": "NCT00072293",
    "briefTitle": "Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases",
    "officialTitle": "A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 931,
    "primaryOutcomeMeasure": "5-year Disease-Free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma\n* Largest tumor lesion \u2264 5 cm\n* Palpable or nonpalpable breast lesion\n\n  * Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions\n* Prior (preoperative) or planned (intraoperative) sentinel node biopsy required\n\n  * At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension\n* No clinical evidence of distant metastases\n\n  * No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:\n\n    * Skeletal pain of unknown cause\n    * Elevated alkaline phosphatase\n    * Bone scan showing hot spots\n* No palpable axillary lymph node(s)\n* No Paget's disease without invasive cancer\n* Hormone receptor status:\n\n  * Estrogen receptor and progesterone receptor known\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Any age\n\nSex\n\n* Female\n\nMenopausal status\n\n* Any status\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* See Disease Characteristics\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* No other prior or concurrent malignancy except the following:\n\n  * Adequately treated basal cell or squamous cell skin cancer\n  * Adequately treated carcinoma in situ of the cervix\n  * Adequately treated in situ melanoma\n  * Contralateral or ipsilateral carcinoma in situ of the breast\n* No psychiatric, addictive, or other disorder that may compromise ability to give informed consent\n* Geographically accessible for follow-up\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* No prior systemic therapy for breast cancer\n* More than 1 year since prior chemopreventive agent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}